Department of Pediatrics
Mark Applebaum is an expert in pediatric cancers and blood diseases. He has a special interest in the treatment of neuroblastoma, sarcomas, and solid tumors, and is actively researching several aspects of neuroblastoma and pediatric solid tumors. His research harnesses the power of large genomic data sets in pediatric oncology to develop new “cancer-specific” targeted strategies that will ultimately improve outcomes while minimizing risk. The main focus of his work is to identify how increased DNA modifications in hypoxia induce changes in the way cells use their DNA to drive clinically aggressive neuroblastoma tumor growth, determine improved risk stratification using these markers, and discover new therapeutic targets.
His research is supported in part by the National Cancer Institute and the University of Chicago Cancer Research Foundation Auxiliary Board. Additionally, he is the recipient of young investigator grants from the Conquer Cancer Foundation and the Bear Necessities Foundation. He received both the Brigid Leventhal Special Merit Award from the Conquer Cancer Foundation and the American Association for Cancer Research–Aflac Inc. Scholar-in-Training Award.
Applebaum received his MD from Northwestern University Feinberg School of Medicine. He completed his residency in pediatrics at the University of California, San Francisco, as well as a fellowship in pediatrics and hematology/oncology at the University of Chicago.